TECH (Bio-Techne Corp.)
Insider Trading Activity
Every open-market purchase and sale reported by TECH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Amy E. Herr | Director | A | — | — |
| 2026-08-19 | James Hippel | CFO | A | — | — |
| 2026-08-19 | William Geist | PRESIDENT, PROTEIN SCIENCES | A | — | — |
| 2026-08-19 | Shane Bohnen | SVP - General Counsel | A | — | — |
| 2026-08-19 | Steven C. Crouse | President - Diag & Spatial Bi | A | — | — |
| 2026-08-19 | Kim Kelderman | Chief Executive Officer | A | — | — |
| 2026-08-18 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | — | — |
| 2026-08-18 | Amy E. Herr | Director | MIXED | — | — |
| 2026-08-18 | Shane Bohnen | SVP - General Counsel | MIXED | — | — |
| 2026-08-18 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2026-08-18 | James Hippel | CFO | MIXED | — | — |
| 2026-08-18 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | — | — |
| 2026-07-31 | James Hippel | CFO | MIXED | — | — |
| 2026-07-30 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2026-07-27 | Shane Bohnen | SVP - General Counsel | MIXED | — | — |
| 2026-06-04 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | — | — |
| 2026-05-12 | Amy E. Herr | Director | MIXED | — | — |
| 2026-05-07 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2026-05-07 | Shane Bohnen | SVP - General Counsel | MIXED | — | — |
| 2026-05-07 | James Hippel | CFO | MIXED | — | — |
| 2026-05-05 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | — | — |
| 2026-04-24 | James Hippel | CFO | MIXED | — | — |
| 2026-04-24 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2026-04-16 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2026-04-07 | Shane Bohnen | SVP - General Counsel | MIXED | — | — |
| 2026-03-04 | Steven C. Crouse | President - Diag & Spatial Bi | A | — | — |
| 2026-02-19 | Amy E. Herr | Director | Sell | — | — |
| 2026-02-05 | Amy E. Herr | Director | MIXED | — | — |
| 2026-02-03 | Matthew McManus | President - Diag & Spatial Bio | MIXED | — | — |
| 2025-11-05 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | — | — |
| 2025-11-05 | James Hippel | CFO | MIXED | — | — |
| 2025-11-05 | Kim Kelderman | Chief Executive Officer | F | — | — |
| 2025-11-03 | ROBERT V BAUMGARTNER | Director | A | — | — |
| 2025-11-03 | Rupert Vessey | Director | A | — | — |
| 2025-11-03 | Judith V. Klimovsky | Director | A | — | — |
| 2025-11-03 | Amy E. Herr | Director | A | — | — |
| 2025-11-03 | Alpna Seth | Director | A | — | — |
| 2025-11-03 | JOHN L HIGGINS | Director | A | — | — |
| 2025-11-03 | JOSEPH D KEEGAN | Director | A | — | — |
| 2025-11-03 | Julie L Bushman | Director | A | — | — |
| 2025-08-27 | ROBERT V BAUMGARTNER | Director | MIXED | — | — |
| 2025-08-27 | Roeland Nusse | Director | MIXED | — | — |
| 2025-08-19 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | — | — |
| 2025-08-19 | Matthew McManus | President - Diag & Spatial Bio | MIXED | — | — |
| 2025-08-19 | Shane Bohnen | SVP - General Counsel | MIXED | — | — |
| 2025-08-19 | Kim Kelderman | Chief Executive Officer | MIXED | — | — |
| 2025-08-19 | Amy E. Herr | Director | MIXED | — | — |
| 2025-08-19 | James Hippel | CFO | MIXED | — | — |
| 2025-08-11 | JOHN L HIGGINS | Director | M | — | — |
| 2025-07-31 | James Hippel | CFO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO, President | 4,983,904 | — |
| — | Chief Executive Officer | 1,287,344 | — |
| — | Director | 392,892 | — |
| — | Director | 288,000 | — |
| — | VP of Research | 260,912 | — |
| — | CFO | 170,183 | — |
| — | SVP - Clinical Controls | 166,960 | — |
| — | Chief Executive Officer | 82,762 | — |
| — | Director | 66,876 | — |
| — | Director | 61,599 | — |
| — | Director | 52,848 | — |
| — | Director | 46,503 | — |
| — | SVP - GENERAL COUNSEL | 31,412 | — |
| — | PRESIDENT, PROTEIN SCIENCES | 24,943 | — |
| — | Director | 24,201 | — |
| — | Director | 19,372 | — |
| — | Director | 15,411 | — |
| — | Director | 15,411 | — |
| — | Director | 10,987 | — |
| — | SVP - General Counsel | 10,360 | — |
| — | President - Diag & Spatial Bi | 10,237 | — |
| — | President - Diag & Spatial Bio | 9,356 | — |
| — | Director | 8,775 | — |
| — | CFO | 8,652 | — |
| — | Director | 7,480 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TECH quote page; the site-wide leaderboard is on the insider transactions hub.